223 related articles for article (PubMed ID: 28863385)
1. Tumour radiosensitivity is associated with immune activation in solid tumours.
Strom T; Harrison LB; Giuliano AR; Schell MJ; Eschrich SA; Berglund A; Fulp W; Thapa R; Coppola D; Kim S; Frakes J; Foekens J; Mulé JJ; Torres-Roca JF
Eur J Cancer; 2017 Oct; 84():304-314. PubMed ID: 28863385
[TBL] [Abstract][Full Text] [Related]
2. Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.
Torres-Roca JF; Fulp WJ; Caudell JJ; Servant N; Bollet MA; van de Vijver M; Naghavi AO; Harris EE; Eschrich SA
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):631-8. PubMed ID: 26461005
[TBL] [Abstract][Full Text] [Related]
3. Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
Cui Y; Li B; Pollom EL; Horst KC; Li R
Clin Cancer Res; 2018 Oct; 24(19):4754-4762. PubMed ID: 29921729
[No Abstract] [Full Text] [Related]
4. Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy.
Mohammadi H; Prince A; Figura NB; Peacock JS; Fernandez DC; Montejo ME; Chon HS; Wenham RM; Eschrich SA; Torres-Roca JF; Ahmed KA
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):496-502. PubMed ID: 31759077
[TBL] [Abstract][Full Text] [Related]
5. Validation of a radiosensitivity molecular signature in breast cancer.
Eschrich SA; Fulp WJ; Pawitan Y; Foekens JA; Smid M; Martens JW; Echevarria M; Kamath V; Lee JH; Harris EE; Bergh J; Torres-Roca JF
Clin Cancer Res; 2012 Sep; 18(18):5134-43. PubMed ID: 22832933
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.
Strom T; Hoffe SE; Fulp W; Frakes J; Coppola D; Springett GM; Malafa MP; Harris CL; Eschrich SA; Torres-Roca JF; Shridhar R
Radiother Oncol; 2015 Oct; 117(1):159-64. PubMed ID: 26235848
[TBL] [Abstract][Full Text] [Related]
7. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy.
Grass GD; Alfonso JCL; Welsh E; Ahmed KA; Teer JK; Pilon-Thomas S; Harrison LB; Cleveland JL; Mulé JJ; Eschrich SA; Enderling H; Torres-Roca JF
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):635-647. PubMed ID: 35289298
[TBL] [Abstract][Full Text] [Related]
8. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
9. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer.
Tanić M; Krivokuća A; Čavić M; Mladenović J; Plesinac Karapandžić V; Beck S; Radulović S; Susnjar S; Janković R
Radiat Oncol; 2018 Oct; 13(1):193. PubMed ID: 30285791
[TBL] [Abstract][Full Text] [Related]
10. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
11. The radiosensitivity index predicts for overall survival in glioblastoma.
Ahmed KA; Chinnaiyan P; Fulp WJ; Eschrich S; Torres-Roca JF; Caudell JJ
Oncotarget; 2015 Oct; 6(33):34414-22. PubMed ID: 26451615
[TBL] [Abstract][Full Text] [Related]
12. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
13. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Jang BS; Kim IA
Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
[TBL] [Abstract][Full Text] [Related]
15. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
[TBL] [Abstract][Full Text] [Related]
16. Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow.
Kunkler IH; Ward C; Langdon SP
Breast; 2015 Nov; 24 Suppl 2():S114-9. PubMed ID: 26429399
[TBL] [Abstract][Full Text] [Related]
17. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
Scott JG; Berglund A; Schell MJ; Mihaylov I; Fulp WJ; Yue B; Welsh E; Caudell JJ; Ahmed K; Strom TS; Mellon E; Venkat P; Johnstone P; Foekens J; Lee J; Moros E; Dalton WS; Eschrich SA; McLeod H; Harrison LB; Torres-Roca JF
Lancet Oncol; 2017 Feb; 18(2):202-211. PubMed ID: 27993569
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
19. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
